Windlas Biotech Launches Rs 47 Crore Share Buyback

Windlas Biotech has approved a Rs 47 crore share buyback at Rs 1,000 per share through the tender offer route, setting April 24 as the record date for shareholder eligibility. The buyback represents 2.23% of the company's equity capital. Promoters are excluded from participating, meaning the entire buyback pool is available to public shareholders. Shares gained approximately 2% on the announcement, a market signal that investors read the move as constructive capital allocation. The tender route creates a structured, time-bound mechanism: eligible shareholders on record as of April 24 can tender shares at the fixed price of Rs 1,000, which likely carried a premium to the prevailing market price at announcement. Buybacks conducted via tender offer are regulated by SEBI norms and require completion within a defined window post-record date. Investors should track acceptance ratios closely, as oversubscription from public float holders could reduce pro-rata allocations and limit effective returns.